Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy
Cancer immunotherapy, which reactivates weakened immune cells of cancer patients, has yielded great success in recent years. Among immunotherapeutic agents, immune checkpoint inhibitors have been of particular interest and have gained approval by the FDA for treatment of cancers. Immune checkpoint b...
Saved in:
Main Authors: | Rangarirai Makuku, Neda Khalili, Sepideh Razi, Mahsa Keshavarz-Fathi, Nima Rezaei |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2021/6661406 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Review on the Application of PD-1 Blockade in EBV-Associated Nasopharyngeal Carcinoma Immunotherapy
by: Jin Bian, et al.
Published: (2022-01-01) -
TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer
by: Huanhuan Yin, et al.
Published: (2020-01-01) -
Escherichia coli combination with PD-1 blockade synergistically enhances immunotherapy in glioblastoma multiforme by regulating the immune cells
by: Guochen Li, et al.
Published: (2025-02-01) -
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
by: Diwakar Davar, et al.
Published: (2015-01-01) -
Stimulation of MMP-1 and CCL2 by NAMPT in PDL Cells
by: Marjan Nokhbehsaim, et al.
Published: (2013-01-01)